Clinical Trial Update: Dose-ranging, PK, Safety, Efficacy Study of Osanetant in Patients With Moderate/Severe VMS Associated With Menopause [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update reporting dose-ranging, PK, safety, and efficacy results for Osanetant in adults with moderate to severe vasomotor symptoms associated wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-menopausal Vasomotor Symptoms

Drugs mentioned

• Osanetant (Osanetant)

Snippet

Sponsor: Acer Therapeutics Inc. | Conditions: Post-menopausal Vasomotor Symptoms | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-08-07